Trial Profile
A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects with New or Recent-Onset Epilepsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Topiramate (Primary) ; Levetiracetam
- Indications Epilepsy; Partial epilepsies; Tonic-clonic epilepsy
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 09 Jun 2020 Status changed from active, no longer recruiting to completed.
- 30 May 2020 The trial has been completed in UK - MHRA according to European Clinical Trials Database record.
- 21 Apr 2020 Planned End Date changed from 6 Oct 2020 to 3 May 2020.